{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:46:17Z","timestamp":1793907977765,"version":"4.8.0"},"reference-count":103,"publisher":"Informa UK Limited","issue":"8-9","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.1080\/17576180.2026.2695220","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:42:37Z","timestamp":1784799757000},"page":"823-837","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Consideration for immunogenicity assay development for oligonucleotide therapeutics"],"prefix":"10.1080","volume":"18","author":[{"given":"Amily Fang-Ju","family":"Jou","sequence":"first","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Hainline","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020260"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0075-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102208"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3nj00418j"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12730"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad067"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46100655"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.5c01565"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0591-y"},{"key":"e_1_3_5_13_1","unstructured":"FDA. Vitravene (fomivirsen) [package insert]. Ionis. 1998."},{"key":"e_1_3_5_14_1","unstructured":"FDA. FDA mipomersen summary review. 2012."},{"key":"e_1_3_5_15_1","unstructured":"FDA. Kynamro (mipomersen sodium) Injection. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203568Orig1s000Lbl.pdf"},{"key":"e_1_3_5_16_1","unstructured":"EMA. Assessment report for mipomersen. 2013."},{"key":"e_1_3_5_17_1","unstructured":"EMEA. EMEA assessment report for volanesorsen. 2018."},{"key":"e_1_3_5_18_1","unstructured":"FDA. Exondys 51 (eteplirsen) [package insert]. Sarepta. 2016."},{"key":"e_1_3_5_19_1","unstructured":"FDA. FDA nusinersen safety review. Research CfDEa; 2017."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0867"},{"key":"e_1_3_5_21_1","unstructured":"FDA. Tegsedi (inotersen) [package insert]. Ionis; 2018."},{"key":"e_1_3_5_22_1","unstructured":"FDA. Inotersen clinical review. 2017."},{"key":"e_1_3_5_23_1","unstructured":"FDA. Golodirsen Clin Rev. 2019."},{"key":"e_1_3_5_24_1","unstructured":"FDA. Viltolarsen clinical review. 2020."},{"key":"e_1_3_5_25_1","unstructured":"FDA. Pharma N. Viltepso (viltolarsen) [Package insert]. 2020."},{"key":"e_1_3_5_26_1","volume-title":"Casimersen clinical review","author":"FDA","year":"2021","unstructured":"FDA. Casimersen clinical review. 2021."},{"key":"e_1_3_5_27_1","unstructured":"FDA. Qalsody (tofersen) [package insert]. Biogen; 2023."},{"key":"e_1_3_5_28_1","unstructured":"FDA. Wainua (eplontersen). [package insert]. AstraZeneca; 2023."},{"key":"e_1_3_5_29_1","unstructured":"FDA. Tryngolza (olezarsen) [package insert]. Ionis. 2024."},{"key":"e_1_3_5_30_1","unstructured":"FDA. RYTELO (imetelstat) [package insert]. Geron; 2024."},{"key":"e_1_3_5_31_1","unstructured":"FDA. FDA patisiran multi-disciplinary review and evaluation. Research CfDEa; 2019."},{"key":"e_1_3_5_32_1","unstructured":"FDA. FDA givosiran multi-disciplinary review and evaluation. Research CfDEa; 2019."},{"key":"e_1_3_5_33_1","unstructured":"EMA. Assessment report for lumasiran. 2020."},{"key":"e_1_3_5_34_1","unstructured":"FDA. Leqvio (inclisiran) [package insert]. Novartis. 2021."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.10.007"},{"key":"e_1_3_5_36_1","unstructured":"Alnylam FDA. Amvuttra (vutrisiran) [package insert]. 2022."},{"key":"e_1_3_5_37_1","unstructured":"FDA. Novo Nordisk. RIVFLOZA (nedosiran). 2023."},{"key":"e_1_3_5_38_1","unstructured":"FDA. Jazz. Defitelio (defibrotide sodium) [package insert]. 2016."},{"key":"e_1_3_5_39_1","unstructured":"FDA. Macugen (pegaptanib sodium). NexStar; 2006."},{"key":"e_1_3_5_40_1","first-page":"1","article-title":"M3 (R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals","author":"FDA","year":"2010","unstructured":"FDA. M3 (R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Guid Ind. 2010:1\u201325.","journal-title":"Guid Ind"},{"key":"e_1_3_5_41_1","volume-title":"Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection","author":"FDA","year":"2019","unstructured":"FDA. Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection. 2019."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-024-00914-w"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95055-x"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1304342"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.5103703"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2014.0506"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666140321100304"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa299"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.02.007"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-020-02403-3"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062004"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802607780487713"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0207-x"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102237"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.112"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00640"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00045a016"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.11.038"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/346818a0"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068810"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2055"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020342"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2016.12.003"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.015"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/app.40293"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00802"},{"key":"e_1_3_5_69_1","volume-title":"Clinical pharmacology considerations for the development of oligonucleotide therapeutics","author":"FDA","year":"2024","unstructured":"FDA. Clinical pharmacology considerations for the development of oligonucleotide therapeutics. Center for Drug Evaluation and Research; 2024."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00802"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102359"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01962.x"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.16.9305"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.3.1617"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2011.0298"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0112"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00741-x"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/21593337251387423"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00649-y"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12422"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2728"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2024.0065"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2024.113657"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2025.2518045"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2007.07.004"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.02.008"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2007.07.005"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2023-0095"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2022.113397"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.10.136"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112856"},{"key":"e_1_3_5_95_1","volume-title":"The immunoassay handbook: theory and applications of ligand binding, ELISA and related techniques","author":"Wild D","year":"2013","unstructured":"Wild D. The immunoassay handbook: theory and applications of ligand binding, ELISA and related techniques. 4th ed. Amsterdam: Elsevier; 2013.","edition":"4"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9599-2"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.06.002"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0181-6"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01118-6"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2020-0091"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.12.285"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12945"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes16121468"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab442"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12860-019-0241-0"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2695220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17576180.2026.2695220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2695220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:25Z","timestamp":1786036405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17576180.2026.2695220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":103,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2026,6,13]]}},"alternative-id":["10.1080\/17576180.2026.2695220"],"URL":"https:\/\/doi.org\/10.1080\/17576180.2026.2695220","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}